AEROGEN PHARMA
Aerogen Pharma is an Irish specialty pharmaceutical company focused on developing the first generation of inhaled drugs specifically designed for use in acute and critical care settings. It operates in Galway, Ireland, and San Mateo, California, and is part of the Aerogen Group, a global leader in aerosol drug delivery. The company aims to create a new standard for aerosol drug delivery to the lungs through innovative technology and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
AEROGEN PHARMA
1660 S. Amphlett Blvd, Suite 360, San Mateo, California 94402, USA
Products
Investigational non-invasive aerosolized surfactant combination for neonatal RDS
An investigational biologic/device combination delivering bovine-derived surfactant via a breath-synchronized vibrating mesh nebulizer and nasal interface for treatment of respiratory distress syndrome in preterm infants.
Breath-synchronized vibrating mesh nebulizer and controller system
A clinical-use nebulizer system consisting of a precision aperture vibrating mesh, respiration sensor and reusable controller designed for consistent aerosol delivery across invasive and non-invasive ventilatory modes.
Investigational non-invasive aerosolized surfactant combination for neonatal RDS
An investigational biologic/device combination delivering bovine-derived surfactant via a breath-synchronized vibrating mesh nebulizer and nasal interface for treatment of respiratory distress syndrome in preterm infants.
Breath-synchronized vibrating mesh nebulizer and controller system
A clinical-use nebulizer system consisting of a precision aperture vibrating mesh, respiration sensor and reusable controller designed for consistent aerosol delivery across invasive and non-invasive ventilatory modes.
Services
Provide external developers access to a high-performance inhalation delivery platform and customized device iterations under commercial licensing or partnership terms.
Advisory services covering aerosol delivery with assisted ventilation and respiratory care, and the regulatory, CMC and clinical aspects of inhaled drug development.
Characterization services for liquid aerosol formulations to support regulatory submissions, including particle sizing, respirable fraction, output rate and deposition efficiency testing.
Program and portfolio management tools and quality system implementation to support clinical development, regulatory submissions and commercialization.
Provide external developers access to a high-performance inhalation delivery platform and customized device iterations under commercial licensing or partnership terms.
Advisory services covering aerosol delivery with assisted ventilation and respiratory care, and the regulatory, CMC and clinical aspects of inhaled drug development.
Characterization services for liquid aerosol formulations to support regulatory submissions, including particle sizing, respirable fraction, output rate and deposition efficiency testing.
Program and portfolio management tools and quality system implementation to support clinical development, regulatory submissions and commercialization.
Expertise Areas
- Inhaled drug/device combination development
- Neonatal and critical-care respiratory therapeutics
- Vibrating mesh aerosol technology
- Clinical trial design and execution for inhaled therapies
Key Technologies
- Vibrating mesh aerosol generation (precision aperture mesh)
- Breath-synchronized aerosol delivery
- Trans-nasal non-invasive pulmonary interfaces
- Particle size control to 1–3 µm MMAD
News & Updates
The license agreement grants Nuance Pharma exclusive rights to develop and commercialize AeroFact™ for treating RDS in Greater China, with Aerogen Pharma receiving upfront payments, equity, milestone payments, and royalties.
The license agreement grants Nuance Pharma exclusive rights to develop and commercialize AeroFact™ for treating RDS in Greater China, with Aerogen Pharma receiving upfront payments, equity, milestone payments, and royalties.